| 释义 |
HBIGBNC⁸⁶⁶⁶⁰⁺⁹
基本例句
=hepatitis B immunoglobulin 乙型肝炎免疫球蛋白
All neonates of two groups were inoculated hepatitis vaccine IMat 0,1 and6 months of age and received HBIG.
两组新生儿再随机分为疫苗组和联合组，疫苗组按免疫计划于出生时、1月和6月接种乙型肝炎疫苗； cnki
ConclusionEntecavir, adefovir or HBIG could be used for the treatment of hepatitis B recurrence after liver transplantation.
结论肝移植术后 HBIG、恩替卡韦、阿德福韦能不同程度控制肝移植术后乙型肝炎复发。 chinagan
Objective:To research hepatitis B immune globulin HBIG preventive effect of mother and infant transmission to the hepatitis B virus HBV.
目的探讨乙肝免疫球蛋白 HBIG预防乙型肝炎病毒 HBV母婴传播的效果。 cnki
Conclusion: The Combined application of HBIG and HBV vaccine to pregnant women may effectively prevent the infection of hepatitis B virus from the mother to infant.
结论：孕妇于孕晚期联合应用 HBIG和乙肝疫苗进行主、被动免疫，可有效地阻断乙型肝炎病毒母婴传播，降低婴儿 HBV感染率。 cnki
Conclusion HBV infected pregnant women with HBIG immunity can decrease the rate of intrauterine transmission and maternal-infantile transmission.
结论对HBV感染孕妇采用 HBIG免疫阻断，可以降低宫内感染及母婴传播的发生率； cnki
Conclusion HBIG before laboring can decrease the HBV intrauterine infection rate.
结论产前应用HBIG可降低 HBV宫内感染率。 cnki
Hepatitis B immunoglobulin HBIG was injected during the pregnancy;
孕期全程进行接种乙肝免疫球蛋白 HBIG； cnki
In intervention group, the bacterin group and combined HBIG group were not significantly different in the rate of supercilious infection and immunity losted P>0.05;
在干预组中，疫苗组和联合组的慢性感染率和免疫失败率无显著差异 P>0.05； cnki
Median follow-up post- HBIG discontinuation was40 range,5-51 months.
在停用 HBIG后平均随访40个月范围为5-51个月。 dxy
Objective To investigate the effect of combined antiviral therapy with Lamivudine and HBIg on reinfection of hepatitis B virusHBV in orthotopic liver transplantationOLT recipients.
目的探讨联合应用拉米呋啶、乙肝免疫球蛋白预防肝移植术后乙肝病毒再感染的疗效。 swhospital
Objective To investigate the effect of combined antiviral therapy with lamivudine and low-dose HBIg on reinfection of hepatitis B virusHBV in orthotopic liver transplantationOLT recipients.
目的探讨拉咪夫定联合小剂量高价人乙肝免疫球蛋白方案预防肝移植术后乙肝病毒再感染的临床疗效。 dictall
Objective To investigate the effect of passive immunization of fetus by injection of HBIG to mothers for prevention of HBV intrauterine infection.
目的探讨经母亲对胎儿行被动免疫在预防乙型肝炎病毒 HBV宫内感染中的作用。 cnki
Objective To study the efficacy of the protocol of lamivudine combined with hepatitis B immunoglobulin HBIGto prevent hepatitis B virusHBV recurrence after liver transplantation.
目的研究拉米夫定联合乙肝免疫球蛋白防治肝移植术后乙肝复发的效果。 dictall
Objective: To evaluate the interruptive effect of hepatitis B virus HBV intrauterine transmission by means of early using of HBV immunoglobulin HBIG.
目的：探讨乙型肝炎病毒 HBV感染孕妇在早孕期开始使用 HBV高效免疫球蛋白 HB IG的干预效果。 cnki
Probability of HBV recurrence was 0% and9% at 2 and4 years after HBIG discontinuation.
停用 HBIG后第二年和第四年的乙肝复发概率分别为0%和9%。 dxy
HBIG does not improve the long term immune efficacy of the YHB vaccine.
联合使用HBIG并不增加基因疫苗的长期免疫效果。 cnki
HBIG was discontinued a median of26 range,0.2-121 months after OLT.
在原位肝移植术后平均26范围0.2-121个月个月 HBIG被停用。 dxy |